Sunshine Biopharma (SBFM) Stock Price, News & Analysis

Company Overview

Sunshine Biopharma (NASDAQ:SBFM) is a clinical-stage biotechnology company focused on the development of novel, small molecule therapies for the treatment of various forms of cancer. The company’s research and development efforts center on the synthesis and preclinical evaluation of synthetic cannabinoid compounds and related analogs designed to target tumor cell proliferation and metastasis. By leveraging proprietary chemistry platforms, Sunshine Biopharma aims to advance its lead candidates through preclinical toxicology studies and toward Investigational New Drug (IND) applications with regulatory authorities.

Beyond its oncology pipeline, Sunshine Biopharma has established a contract research and manufacturing services division. This segment provides custom synthesis, analytical testing and scale‐up production services to pharmaceutical and biotech clients. Operating out of a manufacturing facility in Montreal, Canada, the company offers Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) capabilities, enabling third‐party partners to accelerate development of both small molecule and cannabinoid‐derived APIs.

Founded in 2013, Sunshine Biopharma has built a multidisciplinary leadership team with expertise in medicinal chemistry, pharmacology and regulatory affairs. Chief Executive Officer and Chief Scientific Officer Dr. Ron F. Krabill brings over 25 years of drug discovery experience, while President and Chief Operating Officer Mr. Brent Livingston oversees corporate strategy and business development. The company’s board includes members with extensive backgrounds in oncology research, clinical trial design and intellectual property management.

Sunshine Biopharma’s operations extend primarily across North America, with research collaborations and contract manufacturing partnerships in the United States and Canada. By maintaining an integrated model that combines in‐house drug discovery with client‐driven services, the company seeks to de‐risk its proprietary pipeline while generating revenue through fee‐for‐service engagements. This dual approach positions Sunshine Biopharma to advance its oncology programs toward clinical milestones and support external collaborators in meeting their development objectives.

Key Stats

• Today's Range: $1.50 to $1.59
• 50-Day Range: $1.23 to $1.70
• 52-Week Range: $1.17 to $6.99
• Volume: 79,999 shs
• Average Volume: 602,115 shs
• Market Capitalization: $7.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Sunshine Biopharma Stock Analysis - MarketRank™

Sunshine Biopharma scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sunshine Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sunshine Biopharma has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.97% of the float of Sunshine Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sunshine Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sunshine Biopharma has recently decreased by 5.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sunshine Biopharma does not currently pay a dividend.

Dividend Growth

Sunshine Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.97% of the float of Sunshine Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sunshine Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sunshine Biopharma has recently decreased by 5.58%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.96

News Sentiment

Sunshine Biopharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Sunshine Biopharma this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for SBFM on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.10% of the stock of Sunshine Biopharma is held by insiders.

Percentage Held by Institutions

41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SBFM Stock Analysis - Frequently Asked Questions

How have SBFM shares performed this year?

Sunshine Biopharma's stock was trading at $3.00 at the beginning of 2025. Since then, SBFM shares have decreased by 48.7% and is now trading at $1.54.

How were Sunshine Biopharma's earnings last quarter?

Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.44) earnings per share for the quarter. The firm had revenue of $8.90 million for the quarter. Sunshine Biopharma had a negative trailing twelve-month return on equity of 21.25% and a negative net margin of 13.88%.

When did Sunshine Biopharma's stock split?

Sunshine Biopharma shares reverse split before market open on Wednesday, April 17th 2024.The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Sunshine Biopharma?

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sunshine Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SBFM
• CIK: 1402328
• Web: www.sunshinebiopharma.com
• Phone: (514) 426-6161
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sunshine Biopharma: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +874.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($150.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.13 million
• Net Margins: -13.88%
• Pretax Margin: -14.70%
• Return on Equity: -21.25%
• Return on Assets: -16.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.25
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: $34.87 million
• Price / Sales: 0.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.10 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 4,560,000
• Free Float: 4,551,000
• Market Cap: $7.02 million
• Optionable: Not Optionable
• Beta: 1.44